These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 23822993)

  • 1. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
    Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
    Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of HER-2 Protein is a High-Risk Factor for Patients with Surgically-Resected Stage T3 Gastric Adenocarcinoma.
    Zhang Z; Wang B; Huang G; Wang R; Song J; Lin S; Wang W; Jiang Y; Huang Q; Wang L
    Clin Lab; 2017 Jan; 63(1):115-125. PubMed ID: 28164509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
    Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
    J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
    Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
    Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased MACC1 expression indicates a poor prognosis independent of MET expression in gastric adenocarcinoma.
    Koh YW; Hur H; Lee D
    Pathol Res Pract; 2016 Feb; 212(2):93-100. PubMed ID: 26719224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TFF3 and HER2 expression and their correlation with survival in gastric cancer.
    Gu J; Zheng L; Zhang L; Chen S; Zhu M; Li X; Wang Y
    Tumour Biol; 2015 Apr; 36(4):3001-7. PubMed ID: 25514872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 status in unusual histological variants of gastric adenocarcinomas.
    Giuffrè G; Ieni A; Barresi V; Caruso RA; Tuccari G
    J Clin Pathol; 2012 Mar; 65(3):237-41. PubMed ID: 22067088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
    Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
    Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry as a surrogate for molecular subtyping of gastric adenocarcinoma.
    Gonzalez RS; Messing S; Tu X; McMahon LA; Whitney-Miller CL
    Hum Pathol; 2016 Oct; 56():16-21. PubMed ID: 27342907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of DLX2 correlates with advanced stage of gastric adenocarcinoma.
    Tang P; Huang H; Chang J; Zhao GF; Lu ML; Wang Y
    World J Gastroenterol; 2013 May; 19(17):2697-703. PubMed ID: 23674878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status.
    Inada R; Sekine S; Taniguchi H; Tsuda H; Katai H; Fujiwara T; Kushima R
    World J Gastroenterol; 2015 Feb; 21(7):2159-68. PubMed ID: 25717252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.
    Cheng Y; Zhou J; Li H
    Clin Transl Sci; 2015 Aug; 8(4):320-5. PubMed ID: 25684180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.
    Yan SY; Hu Y; Fan JG; Tao GQ; Lu YM; Cai X; Yu BH; Du YQ
    World J Gastroenterol; 2011 Mar; 17(11):1501-6. PubMed ID: 21472111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers.
    Zhou F; Qiu W; Sun L; Xiang J; Sun X; Sui A; Ding A; Yue L
    APMIS; 2013 Jul; 121(7):582-91. PubMed ID: 23489260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Various ARID1A expression patterns and their clinical significance in gastric cancers.
    Kim YB; Ham IH; Hur H; Lee D
    Hum Pathol; 2016 Mar; 49():61-70. PubMed ID: 26826411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Ki67 Expression has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma.
    Huang G; Chen S; Wang D; Wang R; Lin L; Chen S; Wang L; Huang Q
    Clin Lab; 2016; 62(1-2):141-53. PubMed ID: 27012044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
    Aydin D; Bilici A; Kayahan S; Yavuzer D; Basar M; Aliustaoglu M
    Clin Transl Oncol; 2016 Jun; 18(6):608-16. PubMed ID: 26459248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.